American Heart Journal
Volume 147, Issue 6 , Pages 945-947 , June 2004

Inflammation and restenosis: is there a link?

  • Deepak L Bhatt, MD

      Affiliations

    • Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt MD, FACC, FSCAI, FESC, Director, Interventional Cardiovascular Fellowship, Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F25, 9500 Euclid Ave, Cleveland, OH 44195, USA.

References 

  1. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation. 2002;106:136–140
  2. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med. 2003;70:634–640
  3. Chew DP, Bhatt DL, Robbins MA, et al.  Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 2001;104:992–997
  4. Yen MH, Bhatt DL, Chew DP, et al.  Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes. Am J Med. 2003;115:318–321
  5. Gurm HS, Bhatt DL, Lincoff AM, et al.  Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention (insights from the EPIC, EPILOG, and EPISTENT trials). Heart. 2003;89:1200–1204
  6. Bhatt DL, Chew DP, Lincoff AM, et al.  Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes. Am J Cardiol. 2003;92:136–140
  7. Buffon A, Liuzzo G, Biasucci LM, et al.  Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 1999;34:1512–1521
  8. Walter DH, Fichtlscherer S, Sellwig M, et al.  Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 2001;37:839–846
  9. Dibra A, Mehilli J, Braun S, et al.  Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med. 2003;114:715–722
  10. de Winter RJ, Koch KT, van Straalen JP, et al.  C-reactive protein and coronary events following percutaneous coronary angioplasty. Am J Med. 2003;115:85–90
  11. Chan AW, Bhatt DL, Chew DP, et al.  Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750–1756
  12. Walter DH, Fichtlscherer S, Britten MB, et al.  Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 2001;38:2006–2012
  13. Chan AW, Bhatt DL, Chew DP, et al.  Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691–696
  14. Schillinger M, Exner M, Mlekusch W, et al.  Acute-phase response after stent implantation in the carotid artery (association with 6-month in-stent restenosis). Radiology. 2003;227:516–521
  15. Cipollone F, Marini M, Fazia M, et al.  Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol. 2001;21:327–334
  16. Versaci F, Gaspardone A, Tomai F, et al.  Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40:1935–1942
  17. Ishikawa T, Hatakeyama K, Imamura T, et al.  Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol. 2003;91:287–292
  18. Zairis MN, Ambrose JA, Manousakis SJ, et al.  The impact of plasma levels of C-reactive protein, lipoprotein (a) and homocysteine on the long-term prognosis after successful coronary stenting (the Global Evaluation of New Events and Restenosis After Stent Implantation Study). J Am Coll Cardiol. 2002;40:1375–1382
  19. Marculescu R, Mlekusch W, Exner M, et al.  Interleukin-1 cluster combined genotype and restenosis after balloon angioplasty. Thromb Haemost. 2003;90:491–500
  20. Moses JW, Leon MB, Popma JJ, et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323
  21. Farb A, John M, Acampado E, et al.  Oral everolimus inhibits in-stent neointimal growth. Circulation. 2002;106:2379–2384
  22. Azar RR, McKay RG, Kiernan FJ, et al.  Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol. 1997;80:1476–1478
  23. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al.  Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000;21:1152–1158
  24. Lincoff AM, Kereiakes DJ, Mascelli MA, et al.  Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163–167
  25. Lindmark E, Diderholm E, Wallentin L, et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease (effects of an early invasive or noninvasive strategy). JAMA. 2001;286:2107–2113
  26. Chew DP, Bhatt DL, Robbins MA, et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672–674
  27. Haffner SM, Greenberg AS, Weston WM, et al.  Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  28. Wang K, Zhou Z, Zhou X, et al.  Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. J Am Coll Cardiol. 2001;38:577–582
  29. Wang L, Brown JR, Varki A, et al.  Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest. 2002;110:127–136
  30. Horvath C, Welt FG, Nedelman M, et al.  Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates (inhibitory potential depends on type of injury and leukocytes targeted). Circ Res. 2002;90:488–494
  31. Bhatt DL, Topol EJ. Embolization as a pathological mechanism. In:  Topol EJ editors. Acute coronary syndromes. 2nd ed. New York: Marcel Dekker, Inc; 2000;p. 79–110
  32. Aronow HD, Shishebor MH, Davis DA, et al.  White blood cell count predicts microembolic Doppler signals during carotid stenting (a link between inflammation and embolization). Circulation. 2002;106:II-577
  33. Zhou YF, Csako G, Grayston JT, et al.  Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol. 1999;84:595–598
  34. Bhatt DL. Diffuse coronary disease and atherothrombosis (a rationale for long- term therapy to prevent recurrent ischemic events). J Invasive Cardiol. 2003;15(Suppl B):3–10B

PII: S0002-8703(04)00022-5

doi: 10.1016/j.ahj.2003.12.027

American Heart Journal
Volume 147, Issue 6 , Pages 945-947 , June 2004

Article Tools

* Image Usage & Resolution